NEW YORK (GenomeWeb) – PerkinElmer this week declared a regular quarterly dividend of $.07 per share of common stock, payable on Nov. 10 to all shareholders of record at the close of business on Oct. 20.
Becton Dickinson this week said its board has approved a quarterly dividend of $.73 per common share, payable on Sept. 29 to shareholders of record on Sept. 8.
Eurofins Scientific this week completed its acquisition of GATC, which comprises the acquisition of about 63 percent of LifeCodexx shares owned by GATC. The deal, announced in early June, will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing. The purchase price was not disclosed.
This week, former employees of Courtagen announced that they have teamed up with HealthSavvy subsidiary GeneSavvy to launch what they called "genome-centric biotechnology built to promote vibrant health through their proprietary decision management software." GeneSavvy’s intelligent clinical decision platform, HealthCoach7, is focused on developing and providing diagnostics and treatments for children with ASD, developmental delay, and other complex pediatric and adult disorders, the company said. GeneSavvy will be accepting genetic testing orders starting in August 2017 and will be offering exclusive discounts on genetic testing for previous Courtagen customers and for new customers that are part of the first 1000 orders.
Angle Plc this week announced its financial results for the fiscal year ended April 30. The liquid biopsy company reported revenues increased to £500,000 ($656,732) from £400,000 in 2016. The firm's loss for the year widened to £6.4 million from £5.1 million, reflecting planned investment in patient studies, FDA regulatory clearance, and investment in marketing to drive adoption of Parsortix in research institutions. The company's installed base of Parsortix instruments worldwide grew to 145 from 85 in 2016. Angle had a cash balance of £5.5 million at the end of its fiscal year.
Following positive feedback from the US Food and Drug Administration, SpeeDx said this week it is moving forward with its plan to file a de novo submission for its ResistancePlus MG test, which could be the firm’s first product for the US. The test detects the emerging sexually transmitted infection Mycoplasma genitalium, as well as genetic biomarkers that confer high resistance to azithromycin.
Sonora Quest Laboratories this week was chosen by Commonwealth Primary Care Accountable Care Organization to be the preferred provider of diagnostic test for its patients in Arizona. Commonwealth is a collaboration of 130 independent providers for Medicare patients in that state. Sonora Quest will use its Population Health analytics solutions, which will allow Commonwealth to help physicians close gaps in care, identify risk within patient populations and track individual patients with chronic conditions, such as diabetes and chronic kidney disease, the two organizations said.
Cellectis and its plant genome engineering firm Calyxt this week announced the closing of Calyxt's previously announced initial public offering of just over 8.05 million shares of its common stock at a price of $8 per share. The number of shares issued in the offering includes the exercise in full of the underwriters' option to purchase up to 1.05 million additional shares. Calyxt received approximately $64.4 million in proceeds from the offering before underwriting fees and estimated offering expenses. Following the stock offering, Cellectis owns approximately 79.9 percent of Calyxt's outstanding shares of commons stock. Calyxt now trades on the Nasdaq under the ticker symbol CLXT.
Theradiag this week reported a 12 percent year-over-year increase in second-quarter revenues. The firm said that for the first six months of the year, its revenues rose 9 percent to €5 million ($5.8 million) from €4.6 million. Within that period, its Theranostics business unit revenues rose 43 percent to €2.4 million from €1.7 million in the prior-year first half, driven by the volume of export sales. Its IVD product revenues dipped 10 percent to €2.6 million from €3.0 million.
T2 Biosystems this week joined the Antimicrobials Working Group as its first diagnostics member. T2 is the fourteenth company to join the group, which is focused on combatting drug-resistant infections and developing life-saving innovations. T2 sells the T2Dx Instrument and the T2Candida Panel, both of which have been cleared by the US Food and Drug Administration. The firm is currently conducting clinical studies on its T2Bacteria panel for detection of bacterial sepsis.
Streck announced this week that it has signed a distribution agreement for its products in Jordan with Hamdan for Medical Equipment. Hamdan will distribute Streck’s full portfolio of controls, cell stabilization, and molecular products in the country.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.